HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
|Articles|May 9, 2012
Organizations Speak Out on Stage 2 Rules
Advertisement
Multiple healthcare organizations hustled ahead of Monday's deadline to file comments on the proposed Stage 2 meaningful-use rules for the federally funded electronic health-records incentive payment programs under Medicare and Medicaid.
Read the full story:
Source: ModernHealthcare.com
Among the submitters were the American Medical Association and 98 state and medical specialty societies in a joint, 37-page letter (PDF) to CMS acting Administrator Marilyn Tavenner. Also commenting was the MGMA-ACMPE, in a 29-page missive (DOC) to her.
Advertisement
Related to this article
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease PrEP access.
In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.
Subcutaneous mosunetuzumab plus polatuzumab vedotin boosts responses in relapsed large B-cell lymphoma, helping community oncology care.
Using baseline samples from 177 patients in the VISION/HO141 trial, researchers built a functional prognostic model for CLL that outperformed the CLL-IPI.
Advertisement
Advertisement
Trending on AJMC
1
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
2
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
3
5 Things to Know About the One Big Beautiful Bill Act
4
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
5